IPO registrations (S-1, F-1) · Registrants
CNS Pharmaceuticals, Inc.
- SEC CIK
- 1729427 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2019-06-28, last 2025-05-12; 8 initial registrations, 10 amendments
- Outcome
- Final prospectus filed 2019-11-08; declared effective 2019-11-07; withdrawal requested 2024-07-31
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- NV
- Business address
- 2100 WEST LOOP SOUTH, SUITE 900, Houston, TX 77027
- EIN
- 82-2318545
- Ticker
- CNSP (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- CNS Pharmaceuticals, Inc. on the corporate pages
Offering terms
- Proposed price range
- $4.00–$5.00 per share (S-1/A filed 2019-10-07)
- Final price
- $4.00 per share, within the range (424B4 filed 2019-11-08, an initial public offering)
- Shares sold
- 2,125,000
- Gross proceeds
- $8,500,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CNSP
- Lead underwriters
- share; · (1,564,500 shares)
- Syndicate
- options vest over a three to four-year period; · (435,500)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: CNS PHARMACEUTICALS, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: CNS PHARMACEUTICALS, INC. EXACT (EIN (EXACT))
- Form D issuer: CNS Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- SEC filer: CNS Pharmaceuticals, Inc. EXACT (CIK (EXACT))
Filings 36
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-06-28 | S-1 | S-1 (registration) | CNS Pharmaceuticals, Inc. | 0001683168-19-002054 ↗ |
| 2019-07-16 | S-1/A | S-1/A (amendment) | CNS Pharmaceuticals, Inc. | 0001683168-19-002206 ↗ |
| 2019-08-22 | S-1/A | S-1/A (amendment) | CNS Pharmaceuticals, Inc. | 0001683168-19-002734 ↗ |
| 2019-10-07 | S-1/A | S-1/A (amendment) | CNS Pharmaceuticals, Inc. | 0001683168-19-003197 ↗ |
| 2019-11-07 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-19-002514 ↗ |
| 2019-11-08 | 424B4 | 424B4 (final prospectus) | CNS Pharmaceuticals, Inc. | 0001683168-19-003503 ↗ |
| 2020-09-25 | S-1 | S-1 (registration) | CNS Pharmaceuticals, Inc. | 0001683168-20-003280 ↗ |
| 2020-10-06 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-20-002763 ↗ |
| 2020-12-21 | S-1 | S-1 (registration) | CNS Pharmaceuticals, Inc. | 0001683168-20-004391 ↗ |
| 2020-12-22 | S-1/A | S-1/A (amendment) | CNS Pharmaceuticals, Inc. | 0001683168-20-004411 ↗ |
| 2020-12-22 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-20-003641 ↗ |
| 2020-12-23 | 424B4 | 424B4 (final prospectus) | CNS Pharmaceuticals, Inc. | 0001683168-20-004442 ↗ |
| 2021-02-03 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-21-000423 ↗ |
| 2022-01-31 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-22-000288 ↗ |
| 2022-10-21 | S-1 | S-1 (registration) | CNS Pharmaceuticals, Inc. | 0001683168-22-007006 ↗ |
| 2022-11-15 | S-1/A | S-1/A (amendment) | CNS Pharmaceuticals, Inc. | 0001683168-22-007789 ↗ |
| 2022-11-28 | S-1/A | S-1/A (amendment) | CNS Pharmaceuticals, Inc. | 0001683168-22-008044 ↗ |
| 2022-11-30 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-22-003419 ↗ |
| 2022-12-05 | 424B4 | 424B4 (final prospectus) | CNS Pharmaceuticals, Inc. | 0001683168-22-008177 ↗ |
| 2023-11-30 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-23-003505 ↗ |
| 2023-12-08 | S-1 | S-1 (registration) | CNS Pharmaceuticals, Inc. | 0001683168-23-008734 ↗ |
| 2024-01-10 | S-1/A | S-1/A (amendment) | CNS Pharmaceuticals, Inc. | 0001683168-24-000182 ↗ |
| 2024-01-22 | S-1/A | S-1/A (amendment) | CNS Pharmaceuticals, Inc. | 0001683168-24-000358 ↗ |
| 2024-01-29 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-24-000237 ↗ |
| 2024-01-31 | 424B4 | 424B4 (final prospectus) | CNS Pharmaceuticals, Inc. | 0001683168-24-000580 ↗ |
| 2024-05-17 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-24-001574 ↗ |
| 2024-06-10 | S-1 | S-1 (registration) | CNS Pharmaceuticals, Inc. | 0001683168-24-004062 ↗ |
| 2024-07-12 | S-1 | S-1 (registration) | CNS Pharmaceuticals, Inc. | 0001683168-24-004799 ↗ |
| 2024-07-19 | S-1/A | S-1/A (amendment) | CNS Pharmaceuticals, Inc. | 0001683168-24-004962 ↗ |
| 2024-07-31 | RW | RW (withdrawal request) | CNS Pharmaceuticals, Inc. | 0001683168-24-005165 ↗ |
| 2024-08-02 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-24-002370 ↗ |
| 2025-04-14 | S-1 | S-1 (registration) | CNS Pharmaceuticals, Inc. | 0001683168-25-002548 ↗ |
| 2025-05-12 | S-1/A | S-1/A (amendment) | CNS Pharmaceuticals, Inc. | 0001683168-25-003362 ↗ |
| 2025-05-13 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-25-001564 ↗ |
| 2025-05-14 | 424B4 | 424B4 (final prospectus) | CNS Pharmaceuticals, Inc. | 0001683168-25-003523 ↗ |
| 2026-05-26 | EFFECT | EFFECT (declared effective) | CNS Pharmaceuticals, Inc. | 9999999995-26-001762 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2019-10-07 | S-1/A | registration statement | $4.00–$5.00 | 2,125,000 | - | Nasdaq CNSP | 1 | primary document; range, shares headline, underwriting table 1 | document ↗ | |
| 2019-11-08 | 424B4 | final prospectus | $4.00 | 2,125,000 | $8,500,000 | Nasdaq CNSP | 2 | primary document; price table, shares headline, proceeds computed, underwriting table 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Andraczke Andrzej | Director | 5 | 2019–2023 | ||
| Climaco John M | Director,Officer | Chief Executive Officer | 12 | 2019–2025 | |
| Evans Carl Anthony | Director | 8 | 2019–2024 | ||
| Gumulka Jerzy | Director | 10 | 2019–2025 | ||
| Keyes Jeffry R. | Director | 8 | 2019–2025 | ||
| Priebe Waldemar | TenPercentOwner | 3 | 2019–2023 | ||
| Downs Christopher | Officer | Chief Financial Officer | 15 | 2019–2025 | |
| Charles Faith L. | Director | 7 | 2023–2026 | ||
| Cockroft Bettina M. | Director | 7 | 2023–2025 | ||
| Mahery Amy | Director | 4 | 2024–2025 | ||
| Cortice Biosciences, Inc. | TenPercentOwner | 2 | 2024 | ||
| Levin Rami | Director,Officer; Officer | CEO and President | 3 | 2026 | |
| Faulkner Eric | Officer | Chief Technology Officer | 2 | 2026 | |
| O'Loughlin Steve | Officer | Chief Financial Officer | 2 | 2026 | |
| Fisher Michal | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2026-05-19 | CNS Pharmaceuticals, Inc. | Pharmaceuticals | $22,525,000 | $22,525,000 | 13 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | CNS PHARMACEUTICALS, INC. | TX | State business registries | name and state |
| Contractor | Slate Healthcare LLC | TX | Nonprofit contractors (Form 990) | same street address and ZIP code, 2100 W LOOP S STE 900 77027 (FUZZY: a shared address, not proof of a shared organization) |
| Plan sponsor | CNS PHARMACEUTICALS, INC. | TX | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | CNS Pharmaceuticals, Inc. | TX | Form D private offerings | CIK (EXACT) |
| SEC filer | CNS Pharmaceuticals, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | CNS PHARMACEUTICALS, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, TX first:
- INTROGEN THERAPEUTICS INC TX
- LEXICON PHARMACEUTICALS, INC. TX
- FILANA THERAPEUTICS, INC. TX
- Marker Therapeutics, Inc. TX
- TANOX INC TX
- LUMOS PHARMA, INC. TX
- BIO-PATH HOLDINGS, INC. TX
- Savara Inc TX
- Altrazeal Life Sciences Inc. TX
- Molecular Templates, Inc. TX
In other datasets, the same topic (Health) in TX:
- Nonprofit: AARON ALEXANDERS CLUB NICU (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health